SPECIFICATIONS, STORAGE, AND DISTRIBUTION

合同应向NIDA的药物开发部提供 用于评估的中央机密化合物储存库 潜在的治疗药物。承包商将作为中央 MDD从各种复合体提交者处接收复合体的点。 承包商的部分职责将是分析收到的化合物 纯度，以确保它们适合于在 MDD用于确定潜在治疗药物的测试范例 可卡因和鸦片类药物滥用。承建商也会“蒙蔽”身份。 把这些化合物带到测试地点。这将确保测试 结果将不受任何偏见和先入为主的观念的影响 网站。

The contract shall provide NIDA's Medication Development Division with a centralized confidential repository of compounds for evaluation as potential treatment agents. The Contractor will serve as the central point for receipt of compounds, by MDD, from various compound submitters. Part of the Contractor's duties will be to analyze the compounds received for purity in order to insure that they are suitable for examination in MDD's testing paradigms for determining potential treatment agents for cocaine and opiate abuse. The Contractor will also "blind" the identity of the compounds to the testing sites. This will ensure that the test results will be free from any bias and preconceptions on the part of the sites.